Nakai, Takehiro http://orcid.org/0000-0003-0588-9518
Fukui, Sho
Kidoguchi, Genki
Ikeda, Yukihiko
Kitada, Ayako
Nomura, Atsushi
Tamaki, Hiromichi
Kishimoto, Mitsumasa
Okada, Masato
Article History
Received: 10 May 2022
Revised: 1 August 2022
Accepted: 3 August 2022
First Online: 8 August 2022
Declarations
:
: MK has received consulting fees and/or honoraria from AbbVie, Amgen-Astellas BioPharma, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, Teijin Pharma, and UCB Pharma.MO has received speaking fees and/or honoraria from Eli Lilly and Company, Santen Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, and Abbott Japan.Other authors have no conflicts of interest to declare.